Role of Immunochromatographic Techniques in the Diagnosis of COVID-19

Arham Asif; Muhammad Noman; Hassan Yasin; Shaharyar Ahmad; Muhammad Tahir Naeem; Muhammad Saad Ijaz; Muhammad Abdullah Naeem; Muhammad Waleed Riaz

doi:10.70749/ijbr.v3i3.908

Authors

Arham Asif Madina College of Pharmacy, Faculty of Pharmaceutical Sciences, The University of Faisalabad (TUF), Faisalabad, Punjab, Pakistan.
Muhammad Noman Medical Lab Sciences (MLS), Department of Pathology, Faculty of Medicine and Allied Health Sciences, The University of Faisalabad (TUF), Faisalabad, Punjab, Pakistan.
Hassan Yasin Madina College of Pharmacy, Faculty of Pharmaceutical Sciences, The University of Faisalabad (TUF), Faisalabad, Punjab, Pakistan.
Shaharyar Ahmad Madina College of Pharmacy, Faculty of Pharmaceutical Sciences, The University of Faisalabad (TUF), Faisalabad, Punjab, Pakistan.
Muhammad Tahir Naeem Madina College of Pharmacy, Faculty of Pharmaceutical Sciences, The University of Faisalabad (TUF), Faisalabad, Punjab, Pakistan.
Muhammad Saad Ijaz Madina College of Pharmacy, Faculty of Pharmaceutical Sciences, The University of Faisalabad (TUF), Faisalabad, Punjab, Pakistan.
Muhammad Abdullah Naeem Madina College of Pharmacy, Faculty of Pharmaceutical Sciences, The University of Faisalabad (TUF), Faisalabad, Punjab, Pakistan.
Muhammad Waleed Riaz Madina College of Pharmacy, Faculty of Pharmaceutical Sciences, The University of Faisalabad (TUF), Faisalabad, Punjab, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i3.908

Keywords:

COVID-19, SARS-CoV-2, Rapid Diagnostics, Immunochromatographic Techniques (ICT), Antigen-Antibody Detection

Abstract

The rapid and accurate diagnosis of SARS-CoV-2, the virus responsible for COVID-19, is crucial for controlling its spread and managing public health responses. SARS-CoV-2 is an airborne virus transmitted through direct contact or respiratory droplets from infected individuals. While some patients exhibit clear symptoms, others remain asymptomatic, making early detection essential to prevent further transmission. Diagnostic methods for SARS-CoV-2 primarily rely on two strategies: detecting viral RNA and identifying virus-specific antigens or antibodies. Viral RNA detection through reverse transcription polymerase chain reaction (RT-PCR) remains the gold standard for identifying active infections. In contrast, immunochromatographic techniques (ICT) offer a rapid and cost-effective alternative by detecting viral antigens or host antibodies. Immunological assays such as enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay (CLIA), and lateral flow immunoassay (LFIA) play a complementary role in identifying individuals with current or past infections. This review explores various molecular and serological methods for SARS-CoV-2 detection. RT-PCR offers high sensitivity and specificity, detecting viral RNA in respiratory samples, saliva, blood, urine, and stool within hours. However, it requires expensive equipment and trained personnel, with accuracy affected by sample quality and test kit efficiency. CRISPR-based detection provides high sensitivity and specificity, delivering results within an hour and integrating with lateral flow assays without the need for a thermocycler. Lateral flow assays enable rapid detection within 15 minutes by non-professionals but are limited by delayed antibody production. ELISA and CLIA are useful for immunity assessment, though ELISA lacks early detection capabilities, and CLIA is costly, limiting accessibility in economically challenged regions. Selecting an optimal method depends on available resources, accuracy, and the need for rapid diagnosis.

Downloads

Download data is not yet available.

References

E. Sheikhzadeh, S. Eissa, A. Ismail, and M. Zourob, “Diagnostic techniques for COVID-19 and new developments,” Talanta, vol. 220, p. 121392, Dec. 2020, https://doi.org/10.1016/j.talanta.2020.121392.

H. Harapan et al., “Coronavirus disease 2019 (COVID-19): A literature review,” J Infect Public Health, vol. 13, no. 5, pp. 667–673, May 2020, https://doi.org/10.1016/j.jiph.2020.03.019.

A. Sharma, S. Tiwari, M. K. Deb, and J. L. Marty, “Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies,” Int J Antimicrob Agents, vol. 56, no. 2, p. 106054, Aug. 2020, https://doi.org/10.1016/j.ijantimicag.2020.106054.

P. Huang et al., “A Rapid and Specific Assay for the Detection of MERS-CoV,” Front Microbiol, vol. 9, May 2018, https://doi.org/10.3389/fmicb.2018.01101.

A. R. Sahin, “2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature,” Eurasian J Med Oncol, 2020, https://doi.org/10.14744/ejmo.2020.12220.

F. Li, “Structure, Function, and Evolution of Coronavirus Spike Proteins,” Annu Rev Virol, vol. 3, no. 1, pp. 237–261, Sep. 2016, https://doi.org/10.1146/annurev-virology-110615-042301.

C. Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The Lancet, vol. 395, no. 10223, pp. 497–506, Feb. 2020, https://doi.org/10.1016/S0140-6736(20)30183-5.

N. Post et al., “Antibody response to SARS-CoV-2 infection in humans: A systematic review,” PLoS One, vol. 15, no. 12, p. e0244126, Dec. 2020, https://doi.org/10.1371/journal.pone.0244126.

S. Pecetta et al., “Antibodies, epicenter of SARS-CoV-2 immunology,” Cell Death Differ, vol. 28, no. 2, pp. 821–824, Feb. 2021, https://doi.org/10.1038/s41418-020-00711-w.

W. Yang et al., “Rapid Detection of SARS-CoV-2 Using Reverse transcription RT-LAMP method,” Mar. 02, 2020. https://doi.org/10.1101/2020.03.02.20030130.

P. Zhou et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,” Nature, vol. 579, no. 7798, pp. 270–273, Mar. 2020, https://doi.org/10.1038/s41586-020-2012-7.

M. Tiwari and D. Mishra, “Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design,” Journal of Clinical Virology, vol. 128, p. 104441, Jul. 2020, https://doi.org/10.1016/j.jcv.2020.104441.

A. Naserghandi, S. F. Allameh, and R. Saffarpour, “All about COVID-19 in brief,” New Microbes New Infect, vol. 35, p. 100678, May 2020, https://doi.org/10.1016/j.nmni.2020.100678.

T. Nguyen, D. Duong Bang, and A. Wolff, “2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics,” Micromachines (Basel), vol. 11, no. 3, p. 306, Mar. 2020, https://doi.org/10.3390/mi11030306.

A. J. Rodriguez-Morales et al., “Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis,” Travel Med Infect Dis, vol. 34, p. 101623, Mar. 2020, https://doi.org/10.1016/j.tmaid.2020.101623.

R. Lu et al., “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding,” The Lancet, vol. 395, no. 10224, pp. 565–574, Feb. 2020, https://doi.org/10.1016/S0140-6736(20)30251-8.

B. Diao et al., “Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection,” Mar. 06, 2020. https://doi.org/10.1101/2020.03.04.20031120.

Y. Pan et al., “Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients,” Journal of Infection, vol. 81, no. 1, pp. e28–e32, Jul. 2020, https://doi.org/10.1016/j.jinf.2020.03.051.

N. Chen et al., “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study,” The Lancet, vol. 395, no. 10223, pp. 507–513, Feb. 2020, https://doi.org/10.1016/S0140-6736(20)30211-7.

J. Chen, “Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging viruses,” Microbes Infect, vol. 22, no. 2, pp. 69–71, Mar. 2020, https://doi.org/10.1016/j.micinf.2020.01.004.

Y. Liu, A. A. Gayle, A. Wilder-Smith, and J. Rocklöv, “The reproductive number of COVID-19 is higher compared to SARS coronavirus,” J Travel Med, vol. 27, no. 2, Mar. 2020, https://doi.org/10.1093/jtm/taaa021.

R. Jalandra et al., “Strategies and perspectives to develop SARS-CoV-2 detection methods and diagnostics,” Biomedicine & Pharmacotherapy, vol. 129, p. 110446, Sep. 2020, https://doi.org/10.1016/j.biopha.2020.110446.

Y. Zhou et al., “Sensitivity evaluation of 2019 novel coronavirus (SARS-CoV-2) RT-PCR detection kits and strategy to reduce false negative,” May 05, 2020. https://doi.org/10.1101/2020.04.28.20083956.

F.-X. Lescure et al., “Clinical and virological data of the first cases of COVID-19 in Europe: a case series,” Lancet Infect Dis, vol. 20, no. 6, pp. 697–706, Jun. 2020, https://doi.org/10.1016/S1473-3099(20)30200-0.

K. K.-W. To et al., “Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study,” Lancet Infect Dis, vol. 20, no. 5, pp. 565–574, May 2020, https://doi.org/10.1016/S1473-3099(20)30196-1.

K. Annen et al., “Presence and short‐term persistence of SARS‐CoV ‐2 neutralizing antibodies in COVID ‐19 convalescent plasma donors,” Transfusion (Paris), vol. 61, no. 4, pp. 1148–1159, Apr. 2021, https://doi.org/10.1111/trf.16261.

Y. Pan et al., “SARS-CoV-2-specific immune response in COVID-19 convalescent individuals,” Signal Transduct Target Ther, vol. 6, no. 1, p. 256, Jul. 2021, https://doi.org/10.1038/s41392-021-00686-1.

J. Xu, J. Chen, F. Wen, K. Liu, and Y. Chen, “Detection methods and dynamic characteristics of specific antibodies in patients with COVID-19: A review of the early literature,” Heliyon, vol. 10, no. 3, p. e24580, Feb. 2024, https://doi.org/10.1016/j.heliyon.2024.e24580.

G. Pascarella et al., “COVID‐19 diagnosis and management: a comprehensive review,” J Intern Med, vol. 288, no. 2, pp. 192–206, Aug. 2020, https://doi.org/10.1111/joim.13091.

Q.-X. Long et al., “Antibody responses to SARS-CoV-2 in patients with COVID-19,” Nat Med, vol. 26, no. 6, pp. 845–848, Jun. 2020, https://doi.org/10.1038/s41591-020-0897-1.

Y. Hu, G. Shen, and Q. Li, “Roles of 2 SARS-CoV-2 antibody assays in the diagnosis of corona virus disease 2019,” Laboratory Medicine , vol. 35, pp. 1294–1297, 2020.

Z. Zhang and H. Cheng, “Recent Development in Sample Preparation and Analytical Techniques for Determination of Quinolone Residues in Food Products,” Crit Rev Anal Chem, vol. 47, no. 3, pp. 223–250, May 2017, https://doi.org/10.1080/10408347.2016.1266924.

J. M. Mitchell, M. W. Griffiths, S. A. McEwen, W. B. McNab, and A. J. Yee, “Antimicrobial Drug Residues in Milk and Meat: Causes, Concerns, Prevalence, Regulations, Tests, and Test Performance,” J Food Prot, vol. 61, no. 6, pp. 742–756, Jun. 1998 https://doi.org/10.4315/0362-028X-61.6.742.

J. S. Cullor, “Antibiotic Residue Tests for Mammary Gland Secretions,” Veterinary Clinics of North America: Food Animal Practice, vol. 9, no. 3, pp. 609–620, Nov. 1993, https://doi.org/10.1016/S0749-0720(15)30633-2.

J. Cullor, A. van Eenennaam, J. Dellinger, L. Perani, W. Smith, and L. Jensen, “Antibiotic residue assays: can they be used to test milk from individual cows?,” Vet Med, vol. 87, no. 5, pp. 477–494, 1992.

S. Ahmed et al., “Receptor-based screening assays for the detection of antibiotics residues – A review,” Talanta, vol. 166, pp. 176–186, May 2017, https://doi.org/10.1016/j.talanta.2017.01.057.

B. Cao, H. Yang, J. Song, H. Chang, S. Li, and A. Deng, “Sensitivity and specificity enhanced enzyme-linked immunosorbent assay by rational hapten modification and heterogeneous antibody/coating antigen combinations for the detection of melamine in milk, milk powder and feed samples,” Talanta, vol. 116, pp. 173–180, Nov. 2013, https://doi.org/10.1016/j.talanta.2013.05.009.

C. Cháfer-Pericás, Á. Maquieira, R. Puchades, J. Miralles, and A. Moreno, “Multiresidue determination of antibiotics in feed and fish samples for food safety evaluation. Comparison of immunoassay vs LC-MS-MS,” Food Control, vol. 22, no. 6, pp. 993–999, Jun. 2011, https://doi.org/10.1016/j.foodcont.2010.12.008.

S. Ahmed et al., “Current advances in immunoassays for the detection of antibiotics residues: a review,” Food Agric Immunol, vol. 31, no. 1, pp. 268–290, Jan. 2020, https://doi.org/10.1080/09540105.2019.1707171.

C. Y.-P. Lee, R. T. P. Lin, L. Renia, and L. F. P. Ng, “Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control,” Front Immunol, vol. 11, Apr. 2020, https://doi.org/10.3389/fimmu.2020.00879.

N. Younes et al., “Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2,” Viruses, vol. 12, no. 6, p. 582, May 2020, https://doi.org/10.3390/v12060582.

H.-W. Yu, M. J. Halonen, and I. L. Pepper, “Immunological Methods,” in Environmental Microbiology, Elsevier, 2015, pp. 245–269. https://doi.org/10.1016/B978-0-12-394626-3.00012-0.

Z. Li et al., “Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis,” J Med Virol, vol. 92, no. 9, pp. 1518–1524, Sep. 2020, https://doi.org/10.1002/jmv.25727.

R. Racine and G. M. Winslow, “IgM in microbial infections: Taken for granted?,” Immunol Lett, vol. 125, no. 2, pp. 79–85, Aug. 2009, https://doi.org/10.1016/j.imlet.2009.06.003.

M. Di Domenico, A. De Rosa, and M. Boccellino, “Detection of SARS-COV-2 Proteins Using an ELISA Test,” Diagnostics, vol. 11, no. 4, p. 698, Apr. 2021, https://doi.org/10.3390/diagnostics11040698.

L. Cinquanta, D. E. Fontana, and N. Bizzaro, “Chemiluminescent immunoassay technology: what does it change in autoantibody detection?,” Autoimmunity Highlights, vol. 8, no. 1, p. 9, Dec. 2017, https://doi.org/10.1007/s13317-017-0097-2.

J.W. Hu, E. Wang, and L.J. Kan, “Clinical evaluation of three chemiluminescence assays for detection of novel coronavirus (SARS-CoV-2) antibody kits,” Journal of Modern Laboratory Medicine , vol. 35, pp. 100–105, 2020.

P. Misra et al., “Test concordance and diagnostic accuracy of three serological assays for detection of anti-SARS-CoV-2 antibody: result from a population-based sero-epidemiological study in Delhi,” BMC Infect Dis, vol. 22, no. 1, p. 915, Dec. 2022,https://doi.org/10.1186/s12879-022-07805-5.

D. Wild, Ed., Immunoassay for beginners. In: The immunoassay handbook. Theory and applications of ligand binding, ELISA and related techniques, Fourth. Amsterdam: Springer, 2013.

S. Ahmed et al., “Current advances in immunoassays for the detection of antibiotics residues: a review,” Food Agric Immunol, vol. 31, no. 1, pp. 268–290, Jan. 2020, https://doi.org/10.1080/09540105.2019.1707171.

B. Diao et al., “Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein,” Mar. 10, 2020. https://doi.org/10.1101/2020.03.07.20032524.

B. O’Farrell, “Evolution in Lateral Flow–Based Immunoassay Systems,” in Lateral Flow Immunoassay, Totowa, NJ: Humana Press, 2009, pp. 1–33. https://doi.org/10.1007/978-1-59745-240-3_1.

F. Cui and H. S. Zhou, “Diagnostic methods and potential portable biosensors for coronavirus disease 2019,” Biosens Bioelectron, vol. 165, p. 112349, Oct. 2020, https://doi.org/10.1016/j.bios.2020.112349.

N. M. A. Okba et al., “SARS-CoV-2 specific antibody responses in COVID-19 patients,” Mar. 20, 2020. https://doi.org/10.1101/2020.03.18.20038059.

S. Shahi, S. Zununi Vahed, N. Fathi, and S. Sharifi, “Polymerase chain reaction (PCR)-based methods: Promising molecular tools in dentistry,” Int J Biol Macromol, vol. 117, pp. 983–992, Oct. 2018, https://doi.org/10.1016/j.ijbiomac.2018.05.085.

H. Bai, X. Cai, and X. Zhang, “Landscape Coronavirus Disease 2019 test (COVID-19 test) in vitro -- A comparison of PCR vs Immunoassay vs Crispr-Based test,” Mar. 21, 2020. https://doi.org/10.31219/osf.io/6eagn.

N. Sethuraman, S. S. Jeremiah, and A. Ryo, “Interpreting Diagnostic Tests for SARS-CoV-2,” JAMA, vol. 323, no. 22, p. 2249, Jun. 2020, https://doi.org/10.1001/jama.2020.8259.

D. K. W. Chu et al., “Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia,” Clin Chem, vol. 66, no. 4, pp. 549–555, Apr. 2020, https://doi.org/10.1093/clinchem/hvaa029.

Z. Zhao, H. Cui, W. Song, X. Ru, W. Zhou, and X. Yu, “A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2,” Feb. 27, 2020. https://doi.org/10.1101/2020.02.22.961268.

J. F.-W. Chan et al., “Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens,” J Clin Microbiol, vol. 58, no. 5, Apr. 2020, https://doi.org/10.1128/JCM.00310-20.

X. Cai et al., “A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019,” J Infect Dis, vol. 222, no. 2, pp. 189–193, Jun. 2020, https://doi.org/10.1093/infdis/jiaa243.

J. Zhang et al., “Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing,” Mar. 06, 2020. https://doi.org/10.1101/2020.03.04.20030916.

W. Liu et al., “Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2,” J Clin Microbiol, vol. 58, no. 6, May 2020, https://doi.org/10.1128/JCM.00461-20.

J. Zhao et al., “Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019,” Clinical Infectious Diseases, vol. 71, no. 16, pp. 2027–2034, Nov. 2020, https://doi.org/10.1093/cid/ciaa344.

W. Zhang et al., “Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes,” Emerg Microbes Infect, vol. 9, no. 1, pp. 386–389, Jan. 2020, https://doi.org/10.1080/22221751.2020.1729071.

R. Zhao et al., “Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-expressed full-length SARS-CoV-2 S1 proteins,” Mar. 27, 2020. https://doi.org/10.1101/2020.03.26.20042184.

K. G. Beavis et al., “Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies,” Journal of Clinical Virology, vol. 129, p. 104468, Aug. 2020, https://doi.org/10.1016/j.jcv.2020.104468.

Xiang et al., “Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold-Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19),” Mar. 01, 2020. https://doi.org/10.1101/2020.02.27.20028787.

H. Jiang et al., “Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray,” Mar. 27, 2020. https://doi.org/ 10.1101/2020.03.20.20039495.

T. Hoffman et al., “Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2,” Infect Ecol Epidemiol, vol. 10, no. 1, Jan. 2020, https://doi.org/10.1080/20008686.2020.1754538.

A. Scohy, A. Anantharajah, M. Bodéus, B. Kabamba-Mukadi, A. Verroken, and H. Rodriguez-Villalobos, “Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis,” Journal of Clinical Virology, vol. 129, p. 104455, Aug. 2020, https://doi.org/10.1016/j.jcv.2020.104455.

X. Jia et al., “Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection,” Mar. 03, 2020. https://doi.org/10.1101/2020.02.28.20029025.

F. Xiang et al., “Antibody Detection and Dynamic Characteristics in Patients with Coronavirus Disease 2019,” Clinical Infectious Diseases, vol. 71, no. 8, pp. 1930–1934, Nov. 2020, https://doi.org/10.1093/cid/ciaa461.